Collegium Pharmaceutical (COLL) AI Stock Analysis

• Market Cap: $957.52M
• Dividend Yield: N/A
• Average Volume (3M): 278.95K
• Price to Earnings (P/E): 24.6
• Beta (1Y): 0.26
• Revenue Growth: 17.17%
• EPS Growth: -51.97%
• Country: US
• Employees: 357
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.49
• Shares Outstanding: 32,142,193
• 10 Day Avg. Volume: 335,995
• 30 Day Avg. Volume: 278,951
• PEG Ratio: 0.23
• Price to Book (P/B): 4.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.40
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 0.60
• Enterprise Value/Gross Profit: 3.87
• Enterprise Value/Ebitda: 1.08
• 1Y Price Target: $41.50
• Price Target Upside: 38.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 71 Outperform
• Price Target: $33.00 ▲(10.37%Upside)

Collegium Pharmaceutical's overall stock score of 71 reflects solid financial performance with strong revenue growth and efficient operations, supported by positive earnings call sentiment. However, high leverage and valuation concerns moderate the score. The neutral technical outlook further tempers the overall assessment.

Positive Factors

Product Performance

JornayPM is becoming a main growth engine for COLL, with expected acceleration from increased investments and sales force expansion.

Share Buyback

The company announced it repurchased another $25M in stock, signaling management confidence.

Valuation

The stock price appears undervalued, with potential for significant appreciation as the market recognizes the durability of the company's pain portfolio.

Negative Factors

Generic Competition

Despite potential risks from generic competition, Collegium is projected to generate significant cumulative adj-EBITDA and operating cash flow through 2028, which exceeds its current enterprise value.

Seasonality

Seasonality factors typically lead to a revenue step-down in the first quarter, affecting the company's financial performance compared to the fourth quarter.

Collegium Pharmaceutical Business Overview & Revenue Model

Company Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

How the Company Makes Money

Collegium Pharmaceutical generates revenue primarily through the sale of its proprietary pain management products. The company's key revenue streams come from the commercialization of Xtampza ER and the Nucynta portfolio, which are prescribed by healthcare professionals for managing chronic pain. The company makes money by marketing these products to healthcare providers and partnering with pharmaceutical wholesalers and distributors to ensure broad access to its medications. Additionally, Collegium may engage in strategic partnerships or licensing agreements to expand its market reach and bolster its earnings. Factors such as insurance reimbursement policies, physician adoption, and regulatory approvals significantly contribute to its financial performance.

Collegium Pharmaceutical Financial Statement Overview

Summary

Collegium Pharmaceutical demonstrates robust revenue growth and operational efficiency with strong EBITDA margins. However, increased leverage and declining net profitability may pose risks. The company's cash generation remains strong, supporting its operations despite the challenges.

Income Statement

Collegium Pharmaceutical's income statement shows strong revenue growth, increasing from $566.8M in 2023 to $664.3M in TTM (Trailing-Twelve-Months), representing a growth rate of approximately 15.2%. The gross profit margin is healthy at 57.7% in TTM. However, the net profit margin has decreased from 12.2% in 2024 to 6.6% in TTM, indicating increased expenses or cost pressures. EBIT margin is stable at 21.4% in TTM, and EBITDA margin remains robust at 50.1%, demonstrating good operational efficiency.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 3.60, suggesting significant leverage, which could pose financial risks. However, stockholders' equity has improved slightly to $234.4M in TTM. The equity ratio is 14.4%, indicating moderate reliance on equity financing. Return on Equity (ROE) has decreased from 30.2% in 2024 to 18.7% in TTM, reflecting reduced profitability relative to equity.

Cash Flow

The cash flow statement indicates strong cash generation with a free cash flow of $196.6M in TTM. The free cash flow to net income ratio is 4.48, highlighting effective cash conversion. Operating cash flow to net income ratio is 4.52, suggesting efficient operations. However, there is a decrease in free cash flow from $203.3M in 2024, equating to a negative growth rate, which requires monitoring.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	664.28M	631.45M	566.77M	463.93M	276.87M	310.02M
Gross Profit	383.21M	377.34M	326.17M	209.49M	150.62M	179.84M
EBITDA	332.78M	341.70M	308.33M	168.76M	86.58M	118.07M
Net Income	43.89M	69.19M	48.16M	-25.00M	71.52M	26.75M
Balance Sheet
Total Assets	1.63B	1.66B	1.14B	1.17B	692.08M	643.84M
Cash, Cash Equivalents and Short-Term Investments	197.77M	162.76M	310.55M	173.69M	186.43M	174.12M
Total Debt	844.21M	859.30M	674.28M	872.79M	258.75M	266.58M
Total Liabilities	1.40B	1.43B	947.88M	979.29M	489.15M	457.81M
Stockholders Equity	234.43M	228.84M	195.43M	194.84M	202.93M	186.03M
Cash Flow
Free Cash Flow	196.56M	203.33M	274.29M	122.61M	101.61M	-279.83M
Operating Cash Flow	198.44M	204.98M	274.75M	124.23M	103.56M	93.94M
Investing Cash Flow	-279.31M	-287.76M	-70.81M	-573.69M	-1.94M	-373.77M
Financing Cash Flow	-31.69M	-60.60M	-140.18M	436.72M	-89.30M	286.47M

Collegium Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COLL, the sentiment is Positive. The current price of 29.9 is above the 20-day moving average (MA) of 29.71, above the 50-day MA of 28.77, and below the 200-day MA of 31.28, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 55.59 is Neutral, neither overbought nor oversold. The STOCH value of 65.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COLL.

Collegium Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COLL	71 Outperform	$957.52M	24.64	19.23%	―	17.17%	-51.97%
Sector *	65 Neutral	¥346.03B	10.53	-2.88%	2.63%	11.67%	-7.08%
HROW	60 Neutral	$1.16B	―	-37.23%	―	53.49%	33.18%
NRIX	56 Neutral	$885.86M	―	-64.16%	―	-30.25%	-5.92%
XERS	54 Neutral	$754.33M	―	222.83%	―	29.88%	35.11%
MLYS	53 Neutral	$928.10M	―	-56.31%	―	―	-106.10%
VIR	49 Neutral	$717.46M	―	-44.59%	―	-73.79%	-5.24%

Collegium Pharmaceutical Corporate Events

Collegium Pharmaceutical Approves 2025 Equity Incentive Plan

On May 15, 2025, Collegium Pharmaceutical held its Annual Meeting of Shareholders, where the 2025 Equity Incentive Plan was approved, allowing stock-based awards for company personnel. Additionally, shareholders elected eight directors, approved executive compensation, set the frequency of advisory votes on compensation to annually, and ratified Deloitte & Touche LLP as the independent accounting firm for 2025.

The most recent analyst rating on (COLL) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.

Collegium Pharmaceutical Announces Share Repurchase Agreement

On May 12, 2025, Collegium Pharmaceutical announced an accelerated share repurchase agreement with Jefferies LLC to buy back $25 million of its common stock as part of a $150 million share repurchase program authorized in January 2024. The agreement involves an initial delivery of 692,281 shares and will be settled based on the volume-weighted average prices of the stock, with final settlement expected by the third quarter of 2025. This move is likely to impact the company’s stock value and market positioning, reflecting a strategic financial decision to enhance shareholder value.

The most recent analyst rating on (COLL) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.

Collegium Pharmaceutical Reports 23% Revenue Increase

On May 8, 2025, Collegium Pharmaceutical reported a 23% increase in first-quarter net revenue to $177.8 million, driven by strong performance in its ADHD and pain management portfolios. The company expanded its sales force for Jornay PM, leading to a 24% increase in prescriptions, and authorized a $25 million accelerated share repurchase program. Collegium’s strategic initiatives, including leadership changes and a focus on shareholder value, position it for continued growth and stability in the biopharmaceutical industry.